HRP20161148T1 - Terapija usmjerena na egfr - Google Patents
Terapija usmjerena na egfr Download PDFInfo
- Publication number
- HRP20161148T1 HRP20161148T1 HRP20161148TT HRP20161148T HRP20161148T1 HR P20161148 T1 HRP20161148 T1 HR P20161148T1 HR P20161148T T HRP20161148T T HR P20161148TT HR P20161148 T HRP20161148 T HR P20161148T HR P20161148 T1 HRP20161148 T1 HR P20161148T1
- Authority
- HR
- Croatia
- Prior art keywords
- egfr inhibitor
- use according
- egfr
- group
- inhibitor
- Prior art date
Links
- 108060006698 EGF receptor Proteins 0.000 title 1
- 238000002626 targeted therapy Methods 0.000 title 1
- 229940121647 egfr inhibitor Drugs 0.000 claims 20
- 102000025171 antigen binding proteins Human genes 0.000 claims 3
- 108091000831 antigen binding proteins Proteins 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000004296 neuralgia Diseases 0.000 claims 3
- 208000021722 neuropathic pain Diseases 0.000 claims 3
- 229940126586 small molecule drug Drugs 0.000 claims 3
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000001961 anticonvulsive agent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229960005395 cetuximab Drugs 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- 229960001433 erlotinib Drugs 0.000 claims 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 2
- 229960002584 gefitinib Drugs 0.000 claims 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 229960001972 panitumumab Drugs 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims 1
- 229960001686 afatinib Drugs 0.000 claims 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims 1
- 230000003556 anti-epileptic effect Effects 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 229940125713 antianxiety drug Drugs 0.000 claims 1
- 229940125681 anticonvulsant agent Drugs 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 229930003827 cannabinoid Natural products 0.000 claims 1
- 239000003557 cannabinoid Substances 0.000 claims 1
- 229940065144 cannabinoids Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 229950008001 matuzumab Drugs 0.000 claims 1
- 229960000513 necitumumab Drugs 0.000 claims 1
- 229950008835 neratinib Drugs 0.000 claims 1
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims 1
- 229950010203 nimotuzumab Drugs 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229940127240 opiate Drugs 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 229960000241 vandetanib Drugs 0.000 claims 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 1
- 229950008250 zalutumumab Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Claims (15)
1. Inhibitor EGFR naznačen time da je za uporabu u liječenju neuropatske boli.
2. Inhibitor EGFR za uporabu prema zahtjevu 1, naznačen time da liječeni subjekt iskazuje simptome neuropatske boli i navedeni tretman smanjuje ili modulira simptome neuropatske boli.
3. Inhibitor EGFR za uporabu prema zahtjevu 1, naznačen time da inhibitor EGFR uzrokuje konformacijske promjene EGFR polipeptida.
4. Inhibitor EGFR za uporabu prema zahtjevu 1, naznačen time da inhibitor EGFR ometa interakciju EGFR-ligand.
5. Inhibitor EGFR za uporabu prema zahtjevu 1, naznačen time da je navedeni EGFR inhibitor protein koji veže antigen koji se specifično veže na EGFR polipeptid.
6. Inhibitor EGFR za uporabu prema zahtjevu 5, naznačen time da je navedeni protein koji veže antigen odabran iz skupine koju čine cetuksimab, matuzumab, necitumumab, nimotuzumab, panitumumab, te zalutumumab.
7. Inhibitor EGFR za uporabu prema zahtjevu 5, naznačen time da navedeni protein koji veže antigen odabran iz skupine koju čine Cetuksimab ili Panitumumab.
8. Inhibitor EGFR za uporabu prema zahtjevu 1, naznačen time da je navedeni EGFR inhibitor lijek male molekule.
9. Inhibitor EGFR za uporabu prema zahtjevu 8, naznačen time da je navedeni lijek male molekule odabran iz skupine koju čine afatinib, erlotinib, gefitinib, lapatinib, neratinib i vandetanib.
10. Inhibitor EGFR za uporabu prema zahtjevu 8, naznačen time da je navedeni lijek male molekule odabran iz skupine koju čine Gefitinib i Erlotinib.
11. Inhibitor EGFR za uporabu prema zahtjevu 1, naznačen time da tretirani subjekt je životinja.
12. Inhibitor EGFR za uporabu prema zahtjevu 11, naznačen time da navedena životinja je čovjek.
13. Inhibitor EGFR za uporabu prema zahtjevu 1, naznačen time da se navedeni EGFR inhibitor daje zajedno s najmanje jednim dodatnim terapijskim sredstvom.
14. Inhibitor EGFR za uporabu prema zahtjevu 13, naznačen time da je navedeno najmanje jedno dodatno terapijsko sredstvo odabrano iz skupine koju čine nesteroidni protuupalni lijekovi, steroidni protuupalni lijekovi, lijekovi koji se temelje na opijatima, antidepresivi, antikonvulzijska sredstva, antiepileptici, lijekovi protiv tjeskobe, te kanabinoidi i njihove kombinacije.
15. Inhibitor EGFR uporabu prema bilo kojem od zahtjeva 1 do 14, naznačen time da subjekt koji se liječi nema rak ili prethodno nije bio liječen od raka.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161504737P | 2011-07-06 | 2011-07-06 | |
| PCT/IB2012/001619 WO2013005108A1 (en) | 2011-07-06 | 2012-07-05 | Egfr targeted therapy |
| EP12758888.7A EP2729173B1 (en) | 2011-07-06 | 2012-07-05 | Egfr targeted therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161148T1 true HRP20161148T1 (hr) | 2016-11-18 |
Family
ID=46845782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161148TT HRP20161148T1 (hr) | 2011-07-06 | 2016-09-06 | Terapija usmjerena na egfr |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10980879B2 (hr) |
| EP (1) | EP2729173B1 (hr) |
| JP (6) | JP2014520792A (hr) |
| KR (3) | KR20160084505A (hr) |
| CN (1) | CN103813805B (hr) |
| AU (1) | AU2012279959B2 (hr) |
| BR (1) | BR112014000021A2 (hr) |
| CA (1) | CA2840856C (hr) |
| DK (1) | DK2729173T3 (hr) |
| EA (1) | EA029234B1 (hr) |
| ES (1) | ES2592628T3 (hr) |
| HR (1) | HRP20161148T1 (hr) |
| HU (1) | HUE030501T2 (hr) |
| IL (1) | IL230216A (hr) |
| LT (1) | LT2729173T (hr) |
| MX (1) | MX340536B (hr) |
| PL (1) | PL2729173T3 (hr) |
| PT (1) | PT2729173T (hr) |
| RS (1) | RS55088B1 (hr) |
| SI (1) | SI2729173T1 (hr) |
| WO (1) | WO2013005108A1 (hr) |
| ZA (1) | ZA201400205B (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2729173B1 (en) * | 2011-07-06 | 2016-06-15 | Sykehuset Sorlandet HF | Egfr targeted therapy |
| EA037709B1 (ru) | 2012-12-21 | 2021-05-13 | Сюкехюсе Сёрланне Хф | Способ лечения невропатической боли |
| CN106267368B (zh) * | 2015-06-10 | 2019-08-30 | 北京中科再康生物技术有限公司 | 西妥昔单抗与负载该物质的胶原支架在制备修复脊髓损伤药物中的应用 |
| KR20210053303A (ko) * | 2018-08-31 | 2021-05-11 | 더 존스 홉킨스 유니버시티 | 신경퇴행성 장애를 치료하기 위한 rip 키나제의 억제 |
| US11103509B2 (en) * | 2018-11-07 | 2021-08-31 | University Of Kentucky Research Foundation | Methods of treating pain and/or inflammatory disorders using lapatinib |
| WO2020115108A1 (en) | 2018-12-06 | 2020-06-11 | Sørlandet Sykehus Hf | Egfr inhibitors and their use in the treatment of neuroathic pain |
| WO2021191094A1 (en) | 2020-03-24 | 2021-09-30 | University Court Of The University Of Edinburgh | Erbb-targeted therapies for neuropathic pain |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
| ATE336587T1 (de) | 1994-06-10 | 2006-09-15 | Genvec Inc | Adenoviren-vektor systeme und zelllinien |
| DE69534166T2 (de) | 1994-10-28 | 2006-03-09 | Trustees Of The University Of Pennsylvania | Rekombinanter adenovirus und methoden zu dessen verwendung |
| US5872154A (en) | 1995-02-24 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant adenovirus |
| US5707618A (en) | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
| AU6261696A (en) | 1995-06-05 | 1996-12-24 | Trustees Of The University Of Pennsylvania, The | A replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
| SI0833934T2 (sl) | 1995-06-15 | 2013-04-30 | Crucell Holland B.V. | Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji |
| US5994132A (en) | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
| US5830730A (en) | 1997-05-08 | 1998-11-03 | The Regents Of The University Of California | Enhanced adenovirus-assisted transfection composition and method |
| AU756549B2 (en) | 1997-07-11 | 2003-01-16 | Crucell Holland B.V. | Interleukin-3 gene therapy for cancer |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
| JP2003528029A (ja) | 1998-08-14 | 2003-09-24 | アヴェンティス ファーマシューティカルズ インコーポレイテッド | 遺伝子治療用のアデノウイルス配合物 |
| KR20020013464A (ko) | 1998-08-27 | 2002-02-20 | 추후제출 | 이종 유전자의 전달을 위한 표적화된 아데노바이러스 벡터 |
| AU2001268513A1 (en) | 2000-06-17 | 2002-01-02 | Third Wave Technologies, Inc. | Nucleic acid accessible hybridization sites |
| JP4095895B2 (ja) | 2000-12-01 | 2008-06-04 | マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー．ヴェー． | Ｒｎａ干渉を媒介する短鎖ｒｎａ分子 |
| BR0211111A (pt) | 2001-07-12 | 2004-06-22 | Univ Massachusetts | Molécula de ácido nucleico isolada, vetor, célula hospedeira, transgene, precursor de rna engenheirado, animal transgênico não humano, e, método de induzir a interferência de ácido ribonucleico de um gene alvo em uma célula |
| EP1474433A4 (en) | 2002-02-20 | 2005-02-23 | Sirna Therapeutics Inc | TARGET LOCALIZATION TARGETED BY RNA INTERFERENCE AND TARGET VALIDATION WITH SHORT INTERFERING NUCLEIC ACID (siNA) |
| EP1546397A4 (en) | 2002-09-27 | 2007-10-31 | Cold Spring Harbor Lab | CELL-BASED RNA INTERFERENCE AND METHODS AND COMPOSITIONS RELATING THERETO |
| US20040147428A1 (en) | 2002-11-15 | 2004-07-29 | Pluenneke John D. | Methods of treatment using an inhibitor of epidermal growth factor receptor |
| GB0320793D0 (en) | 2003-09-05 | 2003-10-08 | Astrazeneca Ab | Chemical process |
| WO2005038054A1 (en) | 2003-10-20 | 2005-04-28 | Zicai Liang | METHOD OF MEASURING THE EFFICACY OF siRNA MOLECULES |
| GB0327726D0 (en) | 2003-11-28 | 2003-12-31 | Isis Innovation | Method |
| AU2005232657B2 (en) * | 2004-04-08 | 2010-12-16 | David B. Agus | ErbB antagonists for pain therapy |
| JP5601756B2 (ja) | 2004-12-17 | 2014-10-08 | ベス イスラエル デアコネス メディカル センター， インコーポレイテッド | 細菌によって媒介される遺伝子サイレンシングのための組成物およびその使用方法 |
| EP2054415A1 (en) | 2006-07-14 | 2009-05-06 | Santaris Pharma A/S | Adenosine receptor antagonists |
| US20100216864A1 (en) | 2006-10-09 | 2010-08-26 | Ellen Marie Straarup | RNA Antagonist Compounds for the Modulation of PCSK9 |
| CA2666981A1 (en) | 2006-10-20 | 2008-05-02 | Ercole Biotech, Inc. | Soluble tnf receptors and their use in treatment of disease |
| WO2009048947A1 (en) * | 2007-10-09 | 2009-04-16 | Board Of Regents, The University Of Texas System | Methods of treatment of opioid tolerance, physical dependence, pain, and addiction with inhibitors of certain growth factor receptors |
| WO2010129053A2 (en) | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
| US8828391B2 (en) | 2011-05-17 | 2014-09-09 | Boehringer Ingelheim International Gmbh | Method for EGFR directed combination treatment of non-small cell lung cancer |
| EP2729173B1 (en) * | 2011-07-06 | 2016-06-15 | Sykehuset Sorlandet HF | Egfr targeted therapy |
-
2012
- 2012-07-05 EP EP12758888.7A patent/EP2729173B1/en active Active
- 2012-07-05 CA CA2840856A patent/CA2840856C/en active Active
- 2012-07-05 BR BR112014000021A patent/BR112014000021A2/pt not_active Application Discontinuation
- 2012-07-05 PT PT127588887T patent/PT2729173T/pt unknown
- 2012-07-05 KR KR1020167018053A patent/KR20160084505A/ko active Application Filing
- 2012-07-05 US US14/128,232 patent/US10980879B2/en active Active
- 2012-07-05 WO PCT/IB2012/001619 patent/WO2013005108A1/en active Application Filing
- 2012-07-05 KR KR1020187008240A patent/KR102027715B1/ko active IP Right Grant
- 2012-07-05 PL PL12758888T patent/PL2729173T3/pl unknown
- 2012-07-05 ES ES12758888.7T patent/ES2592628T3/es active Active
- 2012-07-05 LT LTEP12758888.7T patent/LT2729173T/lt unknown
- 2012-07-05 MX MX2013015347A patent/MX340536B/es active IP Right Grant
- 2012-07-05 AU AU2012279959A patent/AU2012279959B2/en active Active
- 2012-07-05 JP JP2014517976A patent/JP2014520792A/ja active Pending
- 2012-07-05 HU HUE12758888A patent/HUE030501T2/en unknown
- 2012-07-05 RS RS20160714A patent/RS55088B1/sr unknown
- 2012-07-05 CN CN201280033570.XA patent/CN103813805B/zh active Active
- 2012-07-05 DK DK12758888.7T patent/DK2729173T3/en active
- 2012-07-05 EA EA201400012A patent/EA029234B1/ru not_active IP Right Cessation
- 2012-07-05 KR KR1020147001414A patent/KR101639141B1/ko active IP Right Grant
- 2012-07-05 SI SI201230682A patent/SI2729173T1/sl unknown
-
2013
- 2013-12-26 IL IL230216A patent/IL230216A/en active IP Right Grant
-
2014
- 2014-01-09 ZA ZA2014/00205A patent/ZA201400205B/en unknown
-
2016
- 2016-05-12 JP JP2016095998A patent/JP6515061B2/ja active Active
- 2016-09-06 HR HRP20161148TT patent/HRP20161148T1/hr unknown
-
2017
- 2017-11-06 JP JP2017214069A patent/JP2018016659A/ja active Pending
-
2019
- 2019-09-18 JP JP2019169072A patent/JP2019210295A/ja not_active Withdrawn
-
2021
- 2021-04-19 US US17/233,805 patent/US20210236635A1/en active Pending
- 2021-12-17 JP JP2021205147A patent/JP2022027977A/ja active Pending
-
2024
- 2024-01-05 JP JP2024000504A patent/JP2024026630A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161148T1 (hr) | Terapija usmjerena na egfr | |
| CY1121148T1 (el) | Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων | |
| Kaiser | Emerging therapies for neovascular age-related macular degeneration: drugs in the pipeline | |
| Bonomo et al. | Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: A systematic review | |
| ECSP16060104A (es) | Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este | |
| UA94899C2 (ru) | Фиксированное дозирование антител к her | |
| SI2530091T1 (en) | PROTITELO ANTI-DLL3 | |
| EA201170136A1 (ru) | Мультимасштабный метод конечных объемов для моделирования резервуара | |
| BRPI0611984A2 (pt) | uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo | |
| RU2018123717A (ru) | Комбинированные лечения, их применения и способы | |
| UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
| TR201905612T4 (tr) | Proteinlerin ve çok değerlikli, hücreye nüfuz eden peptitlerin konjugatları ve bunların kullanımları. | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| HRP20211641T1 (hr) | Bispecifična protutijela anti-vegf/anti-ang-2 i njihova primjena u liječenju vaskularnih očnih bolesti | |
| UA112434C2 (uk) | Антигензв'язувальний білок, який специфічно зв'язується з всма | |
| RU2014138420A (ru) | Антитела против sez6 и способы их применения | |
| AR080698A1 (es) | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e | |
| UA112743C2 (uk) | Терапевтичний dll4-зв'язувальний білок | |
| AR082390A1 (es) | Terapia de combinacion para tratar el cancer que comprende un inhibidor del igf-1r y un inhibidor de akt | |
| RU2014107983A (ru) | Комбинированная терапия иммуноцитокинами | |
| CY1115349T1 (el) | Εξανθρωπισμενα αντι cxcr4 αντισωματα για τη θεραπεια καρκινου | |
| RU2011142183A (ru) | Средство для лечения ревматоидного артрита | |
| ATE534386T1 (de) | Antikrebs-zusammensetzung mit prolin bzw. prolinderivaten und einem antitumorantikörper | |
| JP2015096065A5 (hr) | ||
| BR112022005423A2 (pt) | Interrupção de tecidos tumorais por alvejamento de proteína de ativação de fibroblasto (fap) |